DTD1

Summary

DTD1 (D-aminoacyl-tRNA deacylase 1, HGNC:16219) is a protein-coding gene on chromosome 20p11.23, encoding D-aminoacyl-tRNA deacylase 1 (Q8TEA8). Possible ATPase involved in DNA replication, may facilitate loading of CDC45 onto pre-replication complexes. It is a selective cancer dependency (DepMap: 56.9% of cell lines).

The protein encoded by this gene is similar in sequence to histidyl-tRNA synthetase, which hydrolyzes D-tyrosyl-tRNA(Tyr) into D-tyrosine and free tRNA(Tyr). The encoded protein binds the DNA unwinding element and plays a role in the initiation of DNA replication. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 92675 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 28 total
• Phenotypes (HPO): 4
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 56.9% of screened cell lines
• MANE Select transcript: NM_080820

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16219
Approved symbol	DTD1
Name	D-aminoacyl-tRNA deacylase 1
Location	20p11.23
Locus type	gene with protein product
Status	Approved
Aliases	DUEB, MGC119131, MGC41905, bA379J5.3, bA555E18.1, pqn-68
Ensembl gene	ENSG00000125821
Ensembl biotype	protein_coding
OMIM	610996
Entrez	92675

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 nonsense_mediated_decay

ENST00000377452, ENST00000494921, ENST00000647441, ENST00000916786, ENST00000916787, ENST00000916788, ENST00000916789

RefSeq mRNA: 2 — MANE Select: NM_080820 NM_001318043, NM_080820

CCDS: CCDS13138, CCDS86938

Canonical transcript exons

ENST00000377452 — 6 exons

Exon	Start	End
ENSE00001162838	18744100	18744271
ENSE00001473997	18588054	18588115
ENSE00003504307	18596006	18596241
ENSE00003658417	18593731	18593821
ENSE00003826816	18628127	18628233
ENSE00003899205	18763360	18766644

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 95.36.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 42.1644 / max 187.9243, expressed in 1816 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
183697	19.5516	1795
183696	12.5896	1775
183695	5.1901	1641
183694	4.8330	1655

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	95.36	gold quality
kidney epithelium	UBERON:0004819	95.06	silver quality
palpebral conjunctiva	UBERON:0001812	94.99	gold quality
endothelial cell	CL:0000115	94.66	gold quality
esophagus squamous epithelium	UBERON:0006920	94.45	gold quality
gingiva	UBERON:0001828	94.01	gold quality
middle temporal gyrus	UBERON:0002771	93.98	gold quality
pons	UBERON:0000988	93.85	gold quality
epithelial cell of pancreas	CL:0000083	93.65	silver quality
upper arm skin	UBERON:0004263	92.91	gold quality
tibialis anterior	UBERON:0001385	92.48	silver quality
Brodmann (1909) area 23	UBERON:0013554	92.24	gold quality
parietal pleura	UBERON:0002400	91.83	gold quality
tibia	UBERON:0000979	91.77	gold quality
layer of synovial tissue	UBERON:0007616	91.71	gold quality
deltoid	UBERON:0001476	91.66	gold quality
tendon of biceps brachii	UBERON:0008188	91.62	gold quality
Brodmann (1909) area 46	UBERON:0006483	91.59	gold quality
germinal epithelium of ovary	UBERON:0001304	91.50	gold quality
visceral pleura	UBERON:0002401	91.47	gold quality
synovial joint	UBERON:0002217	91.45	gold quality
adult organism	UBERON:0007023	90.77	gold quality
superior vestibular nucleus	UBERON:0007227	90.62	gold quality
ventral tegmental area	UBERON:0002691	90.47	gold quality
inferior vagus X ganglion	UBERON:0005363	90.33	gold quality
skin of hip	UBERON:0001554	90.32	gold quality
dorsal root ganglion	UBERON:0000044	90.31	gold quality
medial globus pallidus	UBERON:0002477	90.24	gold quality
lateral nuclear group of thalamus	UBERON:0002736	90.16	gold quality
subthalamic nucleus	UBERON:0001906	89.95	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	34.53
E-HCAD-6	yes	26.50
E-ANND-3	yes	7.32
E-MTAB-6524	no	188.72

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

28 targeting DTD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-1290	99.59	69.90	2079
HSA-MIR-302A-5P	99.39	68.21	1913
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-4796-3P	99.08	68.38	1681
HSA-MIR-140-3P	99.04	67.69	1324
HSA-MIR-4650-3P	99.01	68.39	1062
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-4536-5P	98.47	64.39	657
HSA-MIR-6881-3P	98.04	68.24	1777
HSA-MIR-506-5P	98.02	67.41	1065
HSA-MIR-5087	98.01	69.09	965
HSA-MIR-4661-3P	96.81	66.02	342
HSA-MIR-342-3P	96.44	67.48	1344
HSA-MIR-4694-5P	94.62	65.39	532

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 56.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• cloning and identification of novel cDNA which may be associated with FKBP25 (PMID:12392168)
• DUE-B, a c-myc DNA-unwinding element-binding protein, plays an important role in replication in vivo. (PMID:15653697)
• The coordinated binding of DUE-B and Cdc45 to origins and the physical interactions of DUE-B, Cdc45, and TopBP1 suggest that complexes of these proteins are necessary for replication initiation. (PMID:20065034)
• DTD1 variants do not affect the abnormalities of the upper airways in aspirin-intolerant asthma patients (PMID:21479357)
• LDI-PCR revealed a fusion between DTD1 exon 4 and PDGFRB exon 12 in the cases with t(5;14)(q33;q32) and t(5;20)(q33;p11). (PMID:24772479)
• The state of DUE-B phosphorylation is maintained by the equilibrium between Cdc7-dependent phosphorylation and PP2A-dependent dephosphorylation. (PMID:25258324)
• results suggest that DUE-B acts to identify origins by MCM binding and serves as a node for replication protein recruitment and Cdc45 transfer to the prereplication complex (PMID:30037903)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	dtd1	ENSDARG00000044628
mus_musculus	Dtd1	ENSMUSG00000027430
rattus_norvegicus	Dtd1	ENSRNOG00000008746
drosophila_melanogaster	Dtd	FBGN0037898
caenorhabditis_elegans		WBGENE00004151

Paralogs (1): DTD2 (ENSG00000129480)

Protein

Protein identifiers

D-aminoacyl-tRNA deacylase 1 — Q8TEA8 (reviewed: Q8TEA8)

Alternative names: DNA-unwinding element-binding protein B, Gly-tRNA(Ala) deacylase, Histidyl-tRNA synthase-related

All UniProt accessions (3): Q8TEA8, A0A2R8Y6X2, A0A2R8YCT7

UniProt curated annotations — full annotation on UniProt →

Function. Possible ATPase involved in DNA replication, may facilitate loading of CDC45 onto pre-replication complexes. An aminoacyl-tRNA editing enzyme that deacylates mischarged D-aminoacyl-tRNAs. Also deacylates mischarged glycyl-tRNA(Ala), protecting cells against glycine mischarging by AlaRS. Acts via tRNA-based rather than protein-based catalysis; rejects L-amino acids rather than detecting D-amino acids in the active site. By recycling D-aminoacyl-tRNA to D-amino acids and free tRNA molecules, this enzyme counteracts the toxicity associated with the formation of D-aminoacyl-tRNA entities in vivo and helps enforce protein L-homochirality.

Subunit / interactions. Homodimer. Interacts with CDC45 and TOPBP1.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Expressed in many adult and fetal tissues. Highest levels in testis, ovary, spleen and in adult and fetal brain.

Post-translational modifications. Preferentially phosphorylated in cells arrested early in S phase. Phosphorylation in the C-terminus weakens the interaction with CDC45.

Domain organisation. A Gly-cisPro motif from one monomer fits into the active site of the other monomer to allow specific chiral rejection of L-amino acids.

Similarity. Belongs to the DTD family.

RefSeq proteins (2): NP_001304972, NP_543010* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003732	Daa-tRNA_deacyls_DTD	Family
IPR023509	DTD-like_sf	Homologous_superfamily

Pfam: PF02580

Catalyzed reactions (Rhea), 2 shown:

• a D-aminoacyl-tRNA + H2O = a tRNA + a D-alpha-amino acid + H(+) (RHEA:13953)
• glycyl-tRNA(Ala) + H2O = tRNA(Ala) + glycine + H(+) (RHEA:53744)

UniProt features (24 total): strand 6, helix 5, modified residue 3, binding site 3, sequence conflict 2, compositionally biased region 2, chain 1, region of interest 1, short sequence motif 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2OKV	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TEA8-F1	86.04	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 4; 6; 28

Post-translational modifications (3): 205, 197, 204

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 289 (showing top): GOBP_AMINO_ACID_ACTIVATION, MORF_MBD4, YAGI_AML_WITH_INV_16_TRANSLOCATION, MORF_RAB5A, PAL_PRMT5_TARGETS_UP, LFA1_Q6, SHEPARD_CRASH_AND_BURN_MUTANT_UP, GOBP_TRNA_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MITOCHONDRIAL_TRANSLATION, MORF_PSMC2, GOBP_TRANSLATION, MORF_SKP1A, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, MORF_ATOX1

GO Biological Process (3): DNA replication (GO:0006260), tRNA metabolic process (GO:0006399), aminoacyl-tRNA metabolism involved in translational fidelity (GO:0106074)

GO Molecular Function (9): tRNA binding (GO:0000049), DNA binding (GO:0003677), metal ion binding (GO:0046872), D-tyrosyl-tRNA(Tyr) deacylase activity (GO:0051500), Gly-tRNA(Ala) deacylase activity (GO:0106026), aminoacyl-tRNA deacylase activity (GO:0002161), RNA binding (GO:0003723), hydrolase activity (GO:0016787), D-aminoacyl-tRNA deacylase activity (GO:0051499)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	2
aminoacyl-tRNA deacylase activity	2
intracellular membrane-bounded organelle	2
DNA metabolic process	1
DNA biosynthetic process	1
RNA metabolic process	1
tRNA metabolic process	1
regulation of translational fidelity	1
RNA binding	1
cation binding	1
D-aminoacyl-tRNA deacylase activity	1
carboxylic ester hydrolase activity	1
aminoacyl-tRNA metabolism involved in translational fidelity	1
catalytic activity, acting on a tRNA	1
deacylase activity	1
catalytic activity	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

278 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DTD1	DTD2	Q96FN9	792
DTD1	YARS1	P54577	458
DTD1	TARS3	A2RTX5	435
DTD1	YARS2	Q9Y2Z4	434
DTD1	TARS2	Q9BW92	426
DTD1	TARS1	P26639	417
DTD1	DAO	P14920	349
DTD1	GATC	O43716	348
DTD1	ANKRD16	Q6P6B7	331
DTD1	GARS1	P41250	303
DTD1	FARS2	O95363	295
DTD1	EARS2	Q5JPH6	295
DTD1	AARS1	P49588	281
DTD1	MARS1	P56192	266
DTD1	IARS2	Q9NSE4	261

IntAct

14 interactions, top by confidence:

A	B	Type	Score
sseJ	AGPS	psi-mi:“MI:0914”(association)	0.460
DTD1	POLK	psi-mi:“MI:0915”(physical association)	0.400
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
NEK2	DTD1	psi-mi:“MI:0915”(physical association)	0.400
NEK2	DPP9	psi-mi:“MI:0914”(association)	0.350
DISC1	AGRN	psi-mi:“MI:0914”(association)	0.350
	CLIC1	psi-mi:“MI:0914”(association)	0.350
IQCB1	PCP4L1	psi-mi:“MI:0914”(association)	0.350
DTD1	PLS1	psi-mi:“MI:0914”(association)	0.350
DTD1	TNNC2	psi-mi:“MI:0914”(association)	0.350
VCP	SHTN1	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350
INSR	RIMOC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (36): DTD1 (Affinity Capture-MS), CSNK1E (Co-fractionation), DTD1 (Co-fractionation), DTD1 (Co-fractionation), DTD1 (Co-fractionation), DTD1 (Affinity Capture-MS), POLK (Affinity Capture-MS), DTD1 (PCA), DTD1 (Reconstituted Complex), DTD1 (Biochemical Activity), DTD1 (Proximity Label-MS), DTD1 (Biochemical Activity), PLS1 (Affinity Capture-MS), CAMKV (Affinity Capture-MS), DTD1 (Affinity Capture-MS)

ESM2 similar proteins: A0A2B4SJZ1, A3RM20, A4UHP9, C4QX11, F1QGC8, F4J1G1, O56773, O56774, O59835, P03502, P06747, P08013, P0C569, P0DQH9, P12592, P12596, P12598, P12600, P12601, P12602, P13776, P13778, P13781, P16286, P34566, P69253, P69254, P69255, P69256, P69479, P69480, Q0GBX8, Q0GBY3, Q11125, Q1PUD3, Q2U600, Q30NP5, Q5PQ44, Q5UP51, Q5VKP5

Diamond homologs: A0PZW6, A0RJ14, A3CKK5, A3DF46, A4IR99, A4XI81, A5FMN0, A5FSN9, A5I6D9, A5N1Z2, A5UW19, A5VJG2, A6GW89, A6LG62, A6LML3, A7FY07, A7GHS6, A7NLC3, A9BIE9, A9VIN2, B0K0N1, B0K971, B0S1I7, B1I337, B1IME1, B1L0A0, B1L7X6, B1XM75, B2G6X7, B2GBW6, B2TN01, B2V347, B3QL07, B3QTV8, B4S4I3, B4U592, B5YJ89, B6YS15, B7HQG5, B7IDL6

SIGNOR signaling

19 interactions.

A	Effect	B	Mechanism
CDC7	“up-regulates activity”	DTD1	phosphorylation
CSNK2A1	“up-regulates activity”	DTD1	phosphorylation
DTD1	“up-regulates activity”	CDC45	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3403 predictions. Top by Δscore:

Variant	Effect	Δscore
20:18588111:CACAG:C	donor_loss	1.0000
20:18588112:ACAGG:A	donor_loss	1.0000
20:18588113:CAGGT:C	donor_loss	1.0000
20:18588114:AGGT:A	donor_loss	1.0000
20:18588116:G:A	donor_loss	1.0000
20:18588117:T:A	donor_loss	1.0000
20:18593729:A:AG	acceptor_gain	1.0000
20:18593730:G:GG	acceptor_gain	1.0000
20:18593822:G:GG	donor_gain	1.0000
20:18596004:A:AG	acceptor_gain	1.0000
20:18596004:AG:A	acceptor_gain	1.0000
20:18596004:AGG:A	acceptor_gain	1.0000
20:18596005:G:GA	acceptor_loss	1.0000
20:18596005:G:GG	acceptor_gain	1.0000
20:18596005:GG:G	acceptor_gain	1.0000
20:18596005:GGG:G	acceptor_gain	1.0000
20:18596239:AAGG:A	donor_loss	1.0000
20:18596240:AGGTA:A	donor_loss	1.0000
20:18596241:GGT:G	donor_loss	1.0000
20:18596242:GTA:G	donor_loss	1.0000
20:18596243:T:G	donor_loss	1.0000
20:18628124:CAGA:C	acceptor_loss	1.0000
20:18628125:A:AG	acceptor_gain	1.0000
20:18628125:A:G	acceptor_loss	1.0000
20:18628125:AGAT:A	acceptor_gain	1.0000
20:18628126:G:A	acceptor_loss	1.0000
20:18628126:G:GA	acceptor_gain	1.0000
20:18628126:GA:G	acceptor_gain	1.0000
20:18628126:GATG:G	acceptor_gain	1.0000
20:18628230:GCAG:G	donor_gain	1.0000

AlphaMissense

1369 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:18596109:T:C	F80L	0.999
20:18596111:T:A	F80L	0.999
20:18596111:T:G	F80L	0.999
20:18593763:G:C	G26R	0.998
20:18593769:T:C	C28R	0.998
20:18593771:T:G	C28W	0.998
20:18596028:C:A	R53S	0.998
20:18596095:T:C	L75P	0.998
20:18596101:T:A	V77D	0.998
20:18596103:A:C	S78R	0.998
20:18596105:C:A	S78R	0.998
20:18596105:C:G	S78R	0.998
20:18628135:T:C	F127L	0.998
20:18628137:T:A	F127L	0.998
20:18628137:T:G	F127L	0.998
20:18628172:G:A	G139E	0.998
20:18588103:G:C	A11P	0.997
20:18593764:G:A	G26D	0.997
20:18593773:T:A	V29E	0.997
20:18596034:T:C	F55L	0.997
20:18596036:T:A	F55L	0.997
20:18596036:T:G	F55L	0.997
20:18596097:T:C	C76R	0.997
20:18596134:G:A	G88E	0.997
20:18628167:T:A	N137K	0.997
20:18628167:T:G	N137K	0.997
20:18588104:C:A	A11D	0.996
20:18593764:G:T	G26V	0.996
20:18593782:G:A	G32D	0.996
20:18596058:T:A	W63R	0.996

dbSNP variants (sampled 300 via entrez): RS1000014960 (20:18628389 C>G,T), RS1000024230 (20:18661499 G>A), RS1000024954 (20:18654807 A>T), RS1000078053 (20:18722191 C>G), RS1000095428 (20:18756619 A>C,G), RS1000122722 (20:18681017 C>A), RS1000166181 (20:18750235 C>T), RS1000168033 (20:18670604 C>T), RS1000185722 (20:18664093 G>C), RS1000189736 (20:18736716 A>C,G), RS1000193371 (20:18707376 C>T), RS1000207453 (20:18698147 G>A,T), RS1000209615 (20:18756879 A>G), RS1000259478 (20:18713930 G>A,T), RS1000275338 (20:18622218 T>A)

Disease associations

OMIM: gene MIM:610996 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000141	Amenorrhea
HP:0000407	Sensorineural hearing impairment
HP:0010464	Streak ovary

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST003542_160	Night sleep phenotypes	5.000000e-06
GCST004815_1	C-reactive protein (red blood cell fatty acid level interaction)	3.000000e-08
GCST008522_51	Bitter alcoholic beverage consumption	5.000000e-07
GCST008811_40	Alcohol consumption (drinks per week)	1.000000e-08
GCST009391_1903	Metabolite levels	1.000000e-07
GCST009391_1904	Metabolite levels	2.000000e-06
GCST012354_54	Anxiety	1.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004458	C-reactive protein measurement
EFO:0006810	oleic acid measurement
EFO:0010092	bitter alcoholic beverage consumption measurement
EFO:0010463	asymmetric dimethylarginine measurement
EFO:0009863	anxiety measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067312 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.70	Kd	20.18	nM	CHEMBL5653589
7.70	ED50	20.18	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148267: Binding affinity to human DTD1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0202	uM

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, decreases methylation, affects methylation	3
Cyclosporine	increases expression	3
bisphenol A	affects expression, affects cotreatment, increases methylation	2
Aflatoxin B1	decreases expression, increases methylation	2
aristolochic acid I	decreases expression	1
arsenite	affects binding, increases reaction	1
sodium arsenite	decreases expression	1
nickel sulfate	decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	decreases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Testosterone	decreases expression	1
Thiram	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	affects expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651309	Binding	Binding affinity to human DTD1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.